244 related articles for article (PubMed ID: 33515271)
1. Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion.
Kadioglu O; Saeed M; Mahmoud N; Azawi S; Mrasek K; Liehr T; Efferth T
Arch Toxicol; 2021 Mar; 95(3):959-974. PubMed ID: 33515271
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel drug resistance mechanisms by genomic and transcriptomic profiling of glioblastoma cells with mutation-activated EGFR.
Kadioglu O; Saeed MEM; Mahmoud N; Azawi S; Mrasek K; Liehr T; Efferth T
Life Sci; 2021 Nov; 284():119601. PubMed ID: 33991550
[TBL] [Abstract][Full Text] [Related]
3. Genomic and transcriptomic profiling of resistant CEM/ADR-5000 and sensitive CCRF-CEM leukaemia cells for unravelling the full complexity of multi-factorial multidrug resistance.
Kadioglu O; Cao J; Kosyakova N; Mrasek K; Liehr T; Efferth T
Sci Rep; 2016 Nov; 6():36754. PubMed ID: 27824156
[TBL] [Abstract][Full Text] [Related]
4. miR-338-3p confers 5-fluorouracil resistance in p53 mutant colon cancer cells by targeting the mammalian target of rapamycin.
Han J; Li J; Tang K; Zhang H; Guo B; Hou N; Huang C
Exp Cell Res; 2017 Nov; 360(2):328-336. PubMed ID: 28928082
[TBL] [Abstract][Full Text] [Related]
5. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance.
Tsou SH; Chen TM; Hsiao HT; Chen YH
PLoS One; 2015; 10(1):e0116747. PubMed ID: 25635866
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53.
Simões ML; Hockley SL; Schwerdtle T; Gamboa da Costa G; Schmeiser HH; Phillips DH; Arlt VM
Toxicol Appl Pharmacol; 2008 Oct; 232(1):86-98. PubMed ID: 18639569
[TBL] [Abstract][Full Text] [Related]
7. Molecular cytogenetic analysis of chemoresistant non-Hodgkin's lymphoma patients with p53 abnormalities using fluorescence in situ hybridisation and comparative genomic hybridisation.
Foroutan B; Zitzelsberger H; Bauer V; Ruf AA; Baumgartner A; Anderson D
Arch Iran Med; 2011 Sep; 14(5):321-6. PubMed ID: 21888455
[TBL] [Abstract][Full Text] [Related]
8. MyD88 in DNA repair and cancer cell resistance to genotoxic drugs.
Kfoury A; Le Corf K; El Sabeh R; Journeaux A; Badran B; Hussein N; Lebecque S; Manié S; Renno T; Coste I
J Natl Cancer Inst; 2013 Jul; 105(13):937-46. PubMed ID: 23766530
[TBL] [Abstract][Full Text] [Related]
9. p53 mediates hydroxyurea resistance in aneuploid cells of colon cancer.
Fang X; Yin H; Zhang H; Wu F; Liu Y; Fu Y; Yu D; Zong L
Exp Cell Res; 2019 Mar; 376(1):39-48. PubMed ID: 30684461
[TBL] [Abstract][Full Text] [Related]
10. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
[TBL] [Abstract][Full Text] [Related]
11. Exosomal microRNAs derived from colon cancer cells promote tumor progression by suppressing fibroblast TP53 expression.
Yoshii S; Hayashi Y; Iijima H; Inoue T; Kimura K; Sakatani A; Nagai K; Fujinaga T; Hiyama S; Kodama T; Shinzaki S; Tsujii Y; Watabe K; Takehara T
Cancer Sci; 2019 Aug; 110(8):2396-2407. PubMed ID: 31148360
[TBL] [Abstract][Full Text] [Related]
12. Fetal colon cell line FHC exhibits tumorigenic phenotype, complex karyotype, and TP53 gene mutation.
Soucek K; Gajdusková P; Brázdová M; Hýzd'alová M; Kocí L; Vydra D; Trojanec R; Pernicová Z; Lentvorská L; Hajdúch M; Hofmanová J; Kozubík A
Cancer Genet Cytogenet; 2010 Mar; 197(2):107-16. PubMed ID: 20193843
[TBL] [Abstract][Full Text] [Related]
13.
Watanabe S; Tsuchiya K; Nishimura R; Shirasaki T; Katsukura N; Hibiya S; Okamoto R; Nakamura T; Watanabe M
Mol Cancer Res; 2019 Jul; 17(7):1459-1467. PubMed ID: 30988165
[TBL] [Abstract][Full Text] [Related]
14. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.
Holstege H; Horlings HM; Velds A; Langerød A; Børresen-Dale AL; van de Vijver MJ; Nederlof PM; Jonkers J
BMC Cancer; 2010 Nov; 10():654. PubMed ID: 21118481
[TBL] [Abstract][Full Text] [Related]
15. Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy.
Liu C; Banister CE; Buckhaults PJ
Cancer Res; 2019 May; 79(9):2392-2403. PubMed ID: 30862715
[TBL] [Abstract][Full Text] [Related]
16. An N
Uddin MB; Roy KR; Hosain SB; Khiste SK; Hill RA; Jois SD; Zhao Y; Tackett AJ; Liu YY
Biochem Pharmacol; 2019 Feb; 160():134-145. PubMed ID: 30578766
[TBL] [Abstract][Full Text] [Related]
17. Integrative omics analysis of p53-dependent regulation of metabolism.
Huang J; Long Z; Lin W; Liao X; Xie Y; Liu L; Ma W
FEBS Lett; 2018 Feb; 592(3):380-393. PubMed ID: 29323703
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA.
Huang Y; Liu N; Liu J; Liu Y; Zhang C; Long S; Luo G; Zhang L; Zhang Y
Cell Cycle; 2019 Dec; 18(24):3442-3455. PubMed ID: 31726940
[No Abstract] [Full Text] [Related]
19. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
20. Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study.
Daoud SS; Munson PJ; Reinhold W; Young L; Prabhu VV; Yu Q; LaRose J; Kohn KW; Weinstein JN; Pommier Y
Cancer Res; 2003 Jun; 63(11):2782-93. PubMed ID: 12782583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
